跳至主要内容
临床试验/TCTR20170705002
TCTR20170705002已完成4 期

ROLE OF LOW-DOSE ANTITHYROID DRUG THERAPY BEYOND THE RECOMMENDED DURATON IN THE MAINTENANCE OF EUTHYROID STATUS IN GRAVES’ HYPERTHYROIDISM: A RANDOMIZED CONTROLLED STUDY

one0 个研究点目标入组 184 人开始时间: 2017年7月5日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
one
入组人数
184

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 0 N/A (No limit)(—)
性别
All

入选标准

  • Graves' hyperthyroidism was based on clinical and biochemical features including presence of signs and symptoms of thyrotoxicosis, diffuse enlargement of thyroid gland, and elevated serum free thyroid hormones accompanied with suppressed serum thyroid-stimulating hormone (TSH) levels.

排除标准

  • Patients who were suspected to have the causes of hyperthyroidism other than Graves’ disease (i.e., toxic multinodular goiter, toxic adenoma and thyroiditis), radioactive iodine uptake and/or technetium pertechnetate thyroid scan were performed as indicated to verify the diagnosis. Patients who had the causes of hyperthyroidism other than Graves’disease and had recurrent hyperthyroidism were excluded.

研究者

发起方
one

相似试验